Exchange: NASDAQ·Updated 07:45 PM EDT
News
all
press releases
IBRX Stock Sees Sharp UAE-Driven Jump Followed By Early August Pullback
On July 29, UAE regulators approved ImmunityBio’s main cancer drug ANKTIVA for two indications, sparking a rally the next day.
Stocktwits
More News
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?
A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.
Stocktwits
Nasdaq, S&P 500 Futures Rise: Microsoft Lifts AI Mood, Meta Sinks, Investors Brace For Apple, Amazon And PCE – Why MU, IBRX, CAPR, SBUX Are In Focus
Data on Stocktwits showed that retail sentiment remains ‘bearish’ on SPY and QQQ.
Stocktwits
Dow, S&P 500, Nasdaq Futures Rise As Investors Shrug Off Fed Hold, Big Tech Earnings: IBRX, MSFT, SOFI, META In Focus
The Federal Reserve held benchmark interest rates steady for a fifth consecutive session.
Stocktwits
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease
The UAE becomes Anktiva’s fifth regulatory jurisdiction, expanding its footprint to 34 countries and boosting ImmunityBio’s global push.
Stocktwits
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA (nogapendekin alfa inbakicept) across two indications. The...
Business Wire
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat
Investors are also watching for partnership or buyout catalysts as ImmunityBio expands Anktiva internationally and builds its global NK-cell platform.
Stocktwits
IBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conference
Weekend chatter focused on ImmunityBio’s quiet July, with some bulls calling the silence the “quiet before the kraken.”
Stocktwits
SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot
J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.
Stocktwits
<
1
2
>